Mustang Bio, Inc.

NASDAQ (USD): Mustang Bio, Inc. (MBIO)

Last Price

0.321

Today's Change

-0.019 (5.58%)

Day's Change

0.32 - 0.35

Trading Volume

1,344,588

Overview

Market Cap

10 Million

Shares Outstanding

34 Million

Avg Volume

13,508,232

Avg Price (50 Days)

0.34

Avg Price (200 Days)

1.04

PE Ratio

-0.07

EPS

-4.40

Earnings Announcement

12-Aug-2024

Previous Close

0.34

Open

0.34

Day's Range

0.3201 - 0.3499

Year Range

0.128 - 5.475

Trading Volume

1,344,588

Price Change Highlight

1 Day Change

-5.65%

5 Day Change

-20.07%

1 Month Change

-42.21%

3 Month Change

-6.06%

6 Month Change

-76.23%

Ytd Change

-75.69%

1 Year Change

-93.58%

3 Year Change

-99.29%

5 Year Change

-99.31%

10 Year Change

-99.78%

Max Change

-99.78%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment